The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković
Maja
M
Neuropsychiatric Hospital Dr. Ivan Barbot, Popovaca, Croatia. maja.zivkovic@zg.t-com.hr
Mihaljević-Peles
Alma
A
Sagud
Marina
M
Silić
Ante
A
Mihanović
Mate
M
D000328:Adult; D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000235:genetics*; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D003987:Dibenzothiazepines / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005476:Fluphenazine / Q000009:adverse effects / Q000627:therapeutic use; D006580:Genetic Carrier Screening; D005838:Genotype; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016651:Lithium Carbonate / Q000627:therapeutic use; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000235:genetics*; D010464:Perazine / Q000009:adverse effects / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000235:genetics*; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000235:genetics*; D000069348:Quetiapine Fumarate; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D012008:Recurrence; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D017448:Receptors, Dopamine D2; D016651:Lithium Carbonate; D000069348:Quetiapine Fumarate; D010464:Perazine; D019389:Cytochrome P-450 CYP2D6; D003024:Clozapine; D006220:Haloperidol; D018967:Risperidone; D005476:Fluphenazine